← Back to patent-cliff list
Sustained released intravitreal implants(University of Kentucky)
Tier C — Watch / tradeSustained released intravitreal implants(University of Kentucky)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：RT, NLRP3, Inflammasomes
Indications (approved)：地图状萎缩, 年龄相关性黄斑变性, Diabetic macular oedema
Regional status
US
Phase II
2024-04-18
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Sustained released intravitreal implants(University of Kentucky)?
Approved indications include: 地图状萎缩, 年龄相关性黄斑变性, Diabetic macular oedema.
When does the Sustained released intravitreal implants(University of Kentucky) patent expire?
No public expiry year is available for Sustained released intravitreal implants(University of Kentucky) yet; this page updates once verified.
How do I get a quote for Sustained released intravitreal implants(University of Kentucky) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01